Antengene Licenses ATG-106 to K2 Therapeutics
- Antengene has licensed ATG-106, a CDH6 x CD3 bispecific TCE, to K2 Therapeutics, expanding their collaboration around the AnTenGager® platform.
- K2 Therapeutics will receive ATG-106 and a second TCE program enabled by the AnTenGager® platform, with K2's Chief Medical Officer expressing excitement about these therapies.
- The license agreement includes upfront and near-term payments of about USD 20 million to Antengene, potential milestone payments up to USD 960.5 million, and tiered royalties on future net sales.
- ATG-106 is designed to address safety and tolerability challenges found in first-generation TCEs in solid tumors.
41 Articles
41 Articles
The Berkshire Eagle
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China Antengene…
Antengene licenses ATG-106 to K2 Therapeutics
BOSTON, SINGAPORE and HONG KONG, June 22, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: [6996 HK]), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that it has entered into an exclusive license agreement ("Lic…
Coverage Details
Bias Distribution
- 52% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
